Lung cancer (Amsterdam, Netherlands)HumansCarcinomaNon-Small-Cell LungLung NeoplasmsBody Mass Index
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
Christian Rolfo, David E Gerber, Rupesh Kotecha, Jeffrey P Ward, Wallace Akerley, Lukas Weiss, Ariel Naveh, Nadav Shapira, Ticiana Leal, Corey J Langer, LUNAR study investigators
Published: 202510.1016/j.lungcan.2025.108802
Abstract
INTRODUCTION: In the phase III LUNAR study, overall survival (OS) with PD-(L)1 inhibitor or docetaxel was improved by adding Tumor Treating Fields (TTFields) therapy in patients with metastatic non-small cell lung cancer progressing on/after platinum…
Preview only. Read the full abstract at the source